Loading
PET and CT in one machine, so hot spots on the PET are pinned to exact locations on the CT.
Answer a few questions from a report and read the guideline statement that applies, quoted word for word with its source. Educational aids to prepare for an appointment, not advice.
PET/CT acquires PET and CT sequentially on one gantry; the CT provides attenuation correction for the PET data and pins each hot spot to an exact anatomical location. In clinical use since 2001, it is the default form of clinical PET and the standard for staging lymphoma, lung cancer, melanoma and head and neck cancer, combining anatomy with biology in one examination. Total-body PET/CT scanners such as the uEXPLORER and Biograph Vision Quadra image the whole body simultaneously with around 40 times the sensitivity of conventional scanners, enabling ultra-low-dose imaging and dynamic studies that follow tracer kinetics over time. The main drawback is that the CT adds radiation to the PET dose, which matters most in children and in patients scanned repeatedly. PET/CT is two scans in one machine so the biology shown by PET can be read against the anatomy shown by CT.
Sequential PET and CT acquisition on one gantry; CT provides attenuation correction and anatomic localisation.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Fluciclovine F-18 was the first PET tracer approved for finding recurrent prostate cancer after treatment (2016), and has been largely superseded since 2020 by PSMA PET.
The radioactive sugar used in almost every cancer PET scan, approved in the 1990s and made fresh each day by regional cyclotrons.
A PET scan that shows which breast cancer deposits still have oestrogen receptors, helping decide whether hormone therapy will work when biopsy is impractical.
The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).
Telix's ready-to-label kit that lets any nuclear medicine department make the gallium PSMA scan for prostate cancer.
Novartis' gallium PSMA scan kit, approved the same day as Pluvicto as the test that qualifies men for that radioactive drug.
Patients newly diagnosed with an advanced grade 2 or 3 neuroendocrine tumour of the gut or pancreas that shows somatostatin receptors on imaging can now receive lutetium dotatate as their first treatment, gaining more than a year of additional disease control and a much higher chance of tumour shrinkage. It does not settle whether radioligand therapy is better than other first-line options such as capecitabine-temozolomide or everolimus, and long-term marrow safety with earlier use needs surveillance.
Men with metastatic castration-resistant prostate cancer that has progressed after hormonal therapy and chemotherapy, and whose tumours show PSMA on a PET scan, can now receive lutetium-PSMA, which extends life, controls pain and is usually better tolerated than further chemotherapy. It has established a new treatment class in which a scan decides who gets the matching radioactive drug, and it is now being tested earlier in the disease (PSMAfore, PSMAddition).
A blood test can find early, treatable cancers in people who feel well, including cancers for which no screening exists. It is not a replacement for mammography or colonoscopy but a possible addition. Larger randomised trials are needed to show benefit outweighs harm.
PSMA PET-CT is the preferred staging investigation for high-risk prostate cancer and for biochemical recurrence, though most treatment trials were designed with conventional imaging.
It is the evidence behind using PSMA PET when PSA rises after treatment, and it quantifies the limit that matters most: below PSA 0.5 ng/mL, where salvage radiotherapy works best, the scan is negative in nearly two men in three, so a negative scan is not a reason to wait.
Confirmation, by a different route from HD18, that the interim scan can safely direct de-escalation in advanced Hodgkin lymphoma, and that most of the toxicity of escalated BEACOPP can be avoided in the 84 per cent of patients who respond early.
Radiotherapy cannot be omitted in early-stage favourable Hodgkin lymphoma on the basis of a negative interim scan without a clinically relevant loss of tumour control. The scan is better at identifying who needs more than at identifying who needs less.
The UK-authored summary that most NHS hepatobiliary units work from; it names the open questions (type, extent and timing of re-resection; adjuvant chemotherapy) that the trials in this roadmap are trying to answer.
Query for this technology: (TITLE:"PET/CT" OR ABSTRACT:"PET/CT" OR TITLE:"total-body PET" OR ABSTRACT:"total-body PET") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PET/CT, not a curated reading list.
Shares PET-adapted (response-adapted) therapy, Use circulating tumour DNA instead of the interim scan to decide what happens next, Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group, AHL2011.
Shares Cancer imaging, Radiology. Imaging cancer, No clinical claims for imaging-derived biomarkers without phantom and standards compliance, Structured, coded radiology reports for cancer response instead of free text.
Shares Accuracy of gallium-68 PSMA-11 PET in localising recurrent prostate cancer: a prospective single-arm clinical trial, proPSMA: PSMA PET-CT versus conventional imaging for staging high-risk prostate cancer, Chulabhorn Hospital / Chulabhorn Royal Academy, Locametz (kit for Ga-68 gozetotide).
Shares Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group, AHL2011, PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study, GHSG HD16.
Shares Mediso, Nuclear medicine and total-body PET hardware, CT, MRI and PET scanner manufacturing, SPECT/CT.
Shares Imaging core labs and central review, PET-adapted (response-adapted) therapy, FES PET (oestrogen receptor imaging), Deauville score and PET-adapted therapy.
Shares Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group, AHL2011, PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study, GHSG HD16.
Shares Total-body PET for screening and ultra-low-dose imaging, International Atomic Energy Agency: Rays of Hope, Total-body PET for personalised radioligand dosing, European Association of Nuclear Medicine.
Open-source projects that implement or serve this technology, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
The Open Health Imaging Foundation's zero-footprint web DICOM viewer, the front end of many research imaging platforms and the NCI Imaging Data Commons.
The desktop platform for medical image analysis, segmentation, registration and image-guided therapy, with hundreds of extensions and a large research community.
Multi-organ segmentation for PET/CT, built for quantitative nuclear medicine and dosimetry.
Open-source software, hardware and data projects catalogued by a third party, the Open Medical Registry, that bear on this technology. Listing is not endorsement; check each project's own licence and validation before clinical use.
This data-centric AI repository implements a robust deep learning method (LFBNet) for fully automated tumor segmentation in whole-body [18]F-FDG PET/CT images.
From the Open Medical Registry (openmedical.sh), an MIT-licensed catalogue of open-source medicine. Blurbs are one line from each registry record; every project keeps its own licence.